Compass Pathways rises after one-year data for psychedelic-based depression drug

COMPASS Pathways

09/09/2026 12:46

** Shares of Compass Pathways CMPS.O rise 5.3% to $14.78 premarket
** Co reports 52-week data from its late-stage trial showing that additional doses of its psychedelic-based treatment, COMP360, helped sustain reductions in depression symptoms in patients with treatment-resistant depression (TRD)
** CMPS says patients who were initially assigned to the 25 mg COMP360 arm and received an additional dose in the open-label portion of the study showed an average 13-point reduction from baseline on a scale used to measure the severity of depressive episodes at week 52
** Across all participants receiving a 25 mg dose during the open-label phase, response rates were 40%-45% and about 30% achieved remission during the six weeks after treatment
** Compass says a rolling submission of its U.S. new drug application is underway, with final filing expected in Q4
** It expects a potential commercial launch in H1 2027
** As of last close, stock has doubled YTD

 (Reporting by Siddhi Mahatole)
 ((siddhi.mahatole@thomsonreuters.com))